Business Wire

NY-FIRST-EAGLE-INV-MGMT

3.8.2020 12:02:05 CEST | Business Wire | Press release

Share
First Eagle to Open Its First German Office in More Than 80 Years; New Hire Louanges Will Direct International Wholesale Business From Munich

First Eagle Investment Management, LLC (“First Eagle”) is pleased to announce plans to open a branch of First Eagle Investment Management Ltd. in Munich, Germany, through which the firm will serve international wholesale clients in Europe, the Middle East and Africa (EMEA) as well as in other non-US domiciles. The Munich office will be overseen by Matthieu Louanges, who joins First Eagle on August 3 as head of its international wholesale business. Louanges will be stationed in Munich in preparation for the official opening of First Eagle’s office there, expected in late 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005114/en/

“First Eagle traces its origin to Germany, and we are excited to reestablish our local presence there after an absence of more than 80 years,” said Mehdi Mahmud, President and Chief Executive Officer of First Eagle. “Arnhold and S. Bleichroeder, the predecessor firm to First Eagle, represented the amalgamation of two storied German banks: Berlin-based S. Bleichroeder, founded in 1803, and Dresden-based Gebr. Arnhold, founded in 1864. First Eagle’s European roots run deep, and the plan to open an office in continental Europe feels like something of a homecoming. Under the leadership of Matthieu, who has extensive experience working with international clients and building and managing multinational franchises, our Munich location will help us strengthen our partnership with Amundi Asset Management and enhance our client service outreach for non-US clients worldwide.”

Louanges and his team, located in Munich and New York, will be responsible for First Eagle’s international wholesale distribution business, which includes the firm’s distribution partnership with Amundi Asset Management. The European Union and the European continent will continue to be key elements of First Eagle’s international business, and the firm expects Asia and South America to be particularly important regions of business growth moving forward. Highlighting the firm’s commitment to its international business, Louanges will report to Mahmud and will join First Eagle’s Management Committee, marking the first time a Management Committee member has been based outside of the US.

French/German binational Louanges joins First Eagle after more than 20 years at PIMCO, where he was one of the most senior leaders in PIMCO’s EMEA franchise; as Managing Director, he most recently headed up the firm’s global relationship with Allianz. Earlier in his PIMCO tenure, Louanges launched the company’s EMEA insurance channel, which over time evolved into the broader financial institutions group, and he had broad oversight responsibility for PIMCO’s business in Switzerland and France as well as its EMEA client solutions team. Louanges joined PIMCO as a portfolio manager of mutual funds and institutional mandates in 2000 upon its acquisition by Allianz, where he had been playing a similar role.

“I am excited to join First Eagle Investment Management and become a member of its Management Committee,” said Louanges. “While First Eagle’s investment proposition already has a broad client base globally, given the increasingly uncertain economic and market environment, there remains a strong appetite for solutions that combine the potential for attractive returns with downside protection over full market cycles. I look forward to working closely with Mehdi and the rest of my new colleagues to make First Eagle’s time-tested, differentiated investments solutions accessible to international clients and to support our important partnership with Amundi Asset Management.”

Louanges succeeds Robert H. Hackney, Jr., a 25-year veteran of First Eagle. Hackney will remain with the firm, first to assist in the transition of his leadership of the international wholesale distribution business to Louanges and afterward as an advisor to Mahmud and the firm’s leadership team on strategic initiatives. “Robert’s leadership has been integral to the success of our partnership with Amundi Asset Management and our international wholesale business. We have benefited from his keen strategic perspective over the years, and I look forward to his ongoing counsel as we continue to evolve the firm,” said Mahmud.

ABOUT FIRST EAGLE INVESTMENT MANAGEMENT

First Eagle Investment Management is an independent, privately owned investment management firm headquartered in New York with approximately $101 billion in assets under management as of June 30, 2020. Dedicated to providing prudent stewardship of client assets, the firm focuses on active, fundamental and benchmark-agnostic investing, with a strong emphasis on downside protection. Over a long history dating back to 1864, First Eagle has helped its clients avoid permanent impairment of capital and earn attractive returns through widely varied economic cycles—a tradition that is central to its mission today. The firm’s investment capabilities include equity, fixed income, alternative credit and multi-asset strategies. For more information on First Eagle, please visit www.feim.com . For information on First Eagle Alternative Credit, please visit www.feac.com .

First Eagle Investment Management is the brand name for First Eagle Investment Management, LLC and its subsidiary investment advisers.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye